GenesisCare renews RadCalc QA software in 173 radiation oncology centers to offer patient access to more precise, targeted therapy

As the complexity of treatment planning in radiation oncology increases, it is imperative for physicians and radiation therapists to have confidence in the accuracy of secondary dose verification. RadCalc’s independent 3D calculations has allowed GenesisCare and other providers a more accurate analysis of the dose being delivered to their patients with customizable automation designed to fit any clinical workflow. GenesisCare will continue to employ RadCalc in 173 radiation oncology sites across Australia, the United Kingdom, Spain and the United States, with room for further expansion to other sites in the future.  Included in the agreement is also RadCalc’s 3D premium for the UK region and GammaKnife solution.

GenesisCare is the world’s largest provider of radiotherapy – an important treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials. “RadCalc is a comprehensive treatment plan analysis tool that ensures our patients receive the highest quality precision care and treatment plans that have the best chance of improving patient outcomes,” said Tim Fox, GenesisCare’s Global Head of Medical Physics and Clinical Technology.

With their collaboration both parties aim to enhance safety and efficiency in radiation oncology.

About LAP

LAP’s market-leading healthcare systems are used for therapy and quality assurance in radiation therapy. Our laser systems for patient positioning are the global standard in radiotherapy and known for its high product quality. RadCalc is a leading dosimetric verification software for patient QA with more than 2,300 installations worldwide. We develop and design our software and phantoms for precise, reliable testing for a wide range of quality assurance tasks in radiation therapy. Dose calculations, dosimetry checks, and end-to-end tests are just some of our QA product’s features. For more information visit www.lap-laser.com and www.radcalc.com .

About GenesisCare

Sydney-headquartered GenesisCare is an Australian-founded global healthcare company and one of the largest integrated oncology companies. The company’s mission is to design care experiences that get the best possible life outcomes. This is grounded in the belief that care should be focused on the individual, not the condition.

GenesisCare is the world’s largest provider of radiotherapy – an important treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials. With a growing research and trials program numbering more than 150 clinical trials, a contract research organization, and global innovation programs focused on precision medicine and novel therapies, GenesisCare aims to bring new therapies to more patients in need in a more affordable way.

Every year, GenesisCare clinical teams see more than 400,000 people at more than 440 locations. For cancer treatment, that includes more than 300 locations in the U.S., 38 locations in Australia, 14 in the UK and 21 in Spain, with more than 30 new centers under development. The organization employs more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, Europe, and now the U.S. GenesisCare also offers cardiology and sleep services at more than 80 locations across Australia. For more information visit http://www.genesiscare.com/